证券代码：300003 证券简称：乐普医疗 公告编号：2025-049 乐普（北京）医疗器械股份有限公司 关于控股股东部分股权解除质押的公告 公司控股股东蒲忠杰先生及其一致行动人保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 乐普（北京）医疗器械股份有限公司（以下简称：公司）近日接到公司控股 股东蒲忠杰先生的通知，将其持有的本公司部分股权办理了解除质押。具体内容 如下： 一、股份解除质押基本情况 1 | | 持股数量 | 持股 | 累计质押股份 | 占其所 | 占公司 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | | | | 持股份 | 总股本 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | （股） | 比例 | 数量（股） | 比例 | 比例 | 限售和冻结 | 押股份 | 限售和冻结 | 押股份 | | | | | | | | 数量（股 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a decline of 1.26% recently, reflecting broader market trends in the healthcare sector [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,370.1 points with a trading volume of 11.048 billion yuan [1]. - Over the past month, the index has increased by 2.41%, but it has decreased by 7.73% over the last three months and is down 1.09% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.6%), Aier Eye Hospital (8.13%), and United Imaging Healthcare (7.77%) among others [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (60.46%) and the Shanghai Stock Exchange (39.54%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern China Securities Index Healthcare Equipment and Services Link A, and Tianhong China Securities Index Healthcare Equipment and Services ETF [2].

特别提示： 1、 债券代码：123108 债券简称：乐普转 2 2、 转股起止时间：2021 年 10 月 8 日至 2026 年 3 月 29 日 3、 暂停转股时间：2025 年 5 月 19 日至 2025 年 5 月 23 日 4、 恢复转股时间：2025 年 5 月 26 日 证券代码：300003 证券简称：乐普医疗 公告编号：2025-047 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于"乐普转 2"恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据规定，"乐普转 2"将在回售申报期结束后的次一交易日，即 2025 年 5 月 26 日起恢复转股。敬请公司可转换公司债券持有人留意。 1 特此公告。 乐普（北京）医疗器械股份有限公司 董事会 二○二五年五月二十二日 乐普（北京）医疗器械股份有限公司（以下简称：公司）股票2025年3月30 日至2025年5月15日连续三十个交易日的收盘价格低于"乐普转2"当期转股价 27.92元/股的70%（即19.54元/股），且"乐普转2"处于最后两 ...

乐普（北京）医疗器械股份有限公司 关于"乐普转 2" 回售的第四次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、回售价格：100.242 元人民币/张（含息、税） 2、回售期：2025 年 5 月 19 日至 2025 年 5 月 23 日 3、发行人资金到账日：2025 年 5 月 28 日 4、回售款划拨日：2025 年 5 月 29 日 | 证券代码：300003 | 证券简称：乐普医疗 | 公告编号：2025-046 | | --- | --- | --- | | 债券代码：123108 | 债券简称：乐普转 2 | | 5、投资者回售款到账日：2025 年 5 月 30 日 6、回售期内"乐普转 2"停止转股 7、本次回售不具有强制性 8、风险提示：投资者选择回售等同于以人民币 100.242 元/张（含息、税） 卖出持有的"乐普转 2"。截至本公告发出前的最后一个交易日，"乐普转 2" 的收盘价格高于本次回售价格，投资者选择回售可能会带来损失，敬请投资者注 意风险。 乐普（北京）医疗器械股份有限公司（以下简称"公司"） ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-043 债券代码：123108 债券简称：乐普转 2 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司 乐普（北京）医疗器械股份有限公司 董事会 关于公司开立募集资金专户并授权签订 募集资金专户监管协议的公告 乐普（北京）医疗器械股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开了第六届董事会第十四次会议和第六届监事会第十次会议，并于 2025 年 5 月 15 日召开了"乐普转 2"2025 年第一次债券持有人会议、2024 年年度 股东大会，均审议通过了《关于变更募投项目部分募集资金用途及相关事项》的 议案。具体内容详见公司分别于 2025 年 4 月 19 日、2025 年 5 月 15 日在巨潮 资讯网（www.cninfo.com.cn）披露的《关于变更募投项目部分募集资金用途及 相关事项的公告》（公告编号：2025-029）、《"乐普转 2"2025 年第一次债券持 有人会议决议公告》（公告编号：2025-037）、《2024 年年度 ...

乐普（北京）医疗器械股份有限公司 证券代码：300003 证券简称：乐普医疗 公告编号：2025-042 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）第六届董事会第十 五次会议于 2025 年 5 月 19 日在北京市昌平区超前路 37 号公司会议室以现场 及通讯相结合的方式召开，会议通知于 2025 年 5 月 16 日以邮件、电话方式通 知全体董事。会议应出席董事 7 名，实际出席董事 7 名，其中以通讯表决方式出 席会议董事 6 名。本次会议召开符合《公司法》及《公司章程》的相关规定。会 议由董事长蒲忠杰先生主持。出席会议的董事审议并以记名方式投票表决通过了 如下决议： 特此公告。 乐普（北京）医疗器械股份有限公司 董事会 二〇二五年五月十九日 2 鉴于公司已新增可转换公司债券募集资金投资项目"电生理植介入研发"、 "生物类似物司美格鲁肽研发"，项目实施主体分别为乐普医学电子仪器股份有 限公司和乐普药业股份有限公司。为满足公司募投项目发展需要，提升募集资金 使用效率， ...

Group 1 - BYD reported August sales of 174,915 new energy vehicles, a year-on-year increase of 184.84% [1] - Cumulative sales from January to August reached 978,795 units, representing a year-on-year growth of 267.31% [1] - The company sold 5,092 new energy passenger vehicles overseas in August [1] Group 2 - Zhongke Electric's subsidiary plans to establish a joint venture with Chongqing Fudi for the production of anode materials, with a registered capital of 1 billion RMB [2] - Zhongke Electric's subsidiary will contribute 650 million RMB, while Chongqing Fudi will contribute 350 million RMB [2] Group 3 - Yuyuan Group intends to transfer 13% of its shares in Jinhuijiu for approximately 1.937 billion RMB, reducing its stake to 25% [3] - The company plans to further reduce its holdings by more than 5% within the next six months [3] Group 4 - Lizhu Group's recombinant COVID-19 fusion protein vaccine has been included in the emergency use for sequential booster immunization [4] Group 5 - Guanghui Energy plans to repurchase shares worth between 800 million and 1 billion RMB to support employee stock ownership plans [5] Group 6 - Cambrian has launched four cloud-based intelligent chips, although mass sales will require a longer time frame and initial technical service investments [7] Group 7 - LePu Medical has received approval from the China Securities Regulatory Commission for the issuance of Global Depositary Receipts (GDRs) and listing on the Swiss Stock Exchange [9] - The GDR issuance will correspond to no more than 180,458,875 new A-shares [9] Group 8 - Fushi Holdings' subsidiary has entered into an exclusive advertising agency cooperation with the Central Radio and Television Station's automotive channel for three years [10] Group 9 - Guangzhou Port's container throughput in August was 1.981 million TEUs, a year-on-year increase of 2.4% [11] - The total cargo throughput for August was 44.788 million tons, a decrease of 0.6% [11] Group 10 - Ningbo Port expects to complete a container throughput of 3.58 million TEUs in August, a year-on-year increase of 10.2% [12] - The total cargo throughput is projected to decline by 3.0% [12] Group 11 - Ming Tai Aluminum reported a 7% year-on-year decrease in aluminum plate and strip sales in August, while aluminum profile sales increased by 47% [13] Group 12 - Electric Power Investment plans to invest in multiple wind and solar projects, with total static investments of 1.585 billion RMB for wind and 538 million RMB for solar [14] Group 13 - Northeast Pharmaceutical has signed a cooperation agreement with MedAbome for the development of the MAb11-22.1 antibody project [19] Group 14 - New Five Feng plans to acquire equity in Tianxin Seed Industry and several other companies for a total price of approximately 2.208 billion RMB [26] Group 15 - Sumeida's subsidiary plans to transfer 100% equity of eight photovoltaic power station project companies, with an estimated transaction value of 657 million RMB [27] Group 16 - *ST Tongzhou intends to acquire 51% equity in Tongtaiwei, fulfilling the capital contribution obligation of 10.2 million RMB [29] Group 17 - Tianyin Holdings' subsidiary plans to invest 120 million RMB in Xundong Xintong to acquire 40% equity [30] Group 18 - Hainan Haiyao plans to publicly transfer 43% equity in Shanghai Lishengte to attract new investors [31] Group 19 - New Asia Process plans to transfer 7.76% of its shares to Xiangcai New Materials at a price of 5.274 RMB per share [32] Group 20 - Lanwei Medical plans to raise no more than 664 million RMB through a private placement for provincial laboratory construction projects [34] Group 21 - Lida New Materials plans to issue convertible bonds to raise no more than 300 million RMB for a new aluminum material project [35] Group 22 - Gekewei has successfully launched its 12-inch CIS integrated circuit project, achieving over 95% yield [51] Group 23 - Baijin Medical's tricuspid valve ring product has received registration approval [52] Group 24 - Shanghai Pharmaceuticals has received approval to initiate Phase I clinical trials for a recombinant anti-CD20 humanized monoclonal antibody [53] Group 25 - Junda Co. has increased the production capacity of its solar cell production base project from 8GW to 10GW [54]

Core Viewpoint - The electrophysiology device market in China is experiencing rapid growth due to an aging population, increasing prevalence of arrhythmias, improved early screening rates, and advancements in electrophysiological procedures, with the market expected to reach over 40 billion yuan by 2032 [1][10][21]. Industry Overview - Electrophysiology devices are used to monitor and study electrical activities in biological systems, widely applied in medical, research, and clinical diagnosis fields. Common products include ECG machines, EEG machines, EMG machines, and electrophysiological navigation systems [2][4]. Industry Environment - The number of patients with rapid arrhythmias in China is projected to reach 28.2 million by 2024, driving demand for treatment. Electrophysiological surgeries have become a primary treatment method due to their advantages such as minimal invasiveness and high safety [6][8]. Industry Status - The market size for electrophysiology devices in China has grown from 2.42 billion yuan in 2017 to 12.55 billion yuan in 2024. The surgical volume for electrophysiology has increased from 138,000 cases in 2017 to 456,000 cases in 2024, indicating significant growth potential [10][8]. Competitive Landscape - The market is dominated by foreign companies such as Johnson & Johnson, Abbott, and Medtronic, which hold a combined market share of over 64%. Domestic companies like Huatai Medical and MicroPort EP have a much smaller share, indicating a high concentration in the industry [12][14]. Key Enterprises - MicroPort EP focuses on innovative medical devices for electrophysiology and has achieved significant revenue growth, with a projected income of 413 million yuan in 2024, up 25.51% [17]. Huatai Medical, specializing in electrophysiology and interventional medical devices, expects a revenue of 440 million yuan in 2024, reflecting a 19.73% increase [19]. Development Trends 1. **Accelerated Domestic Substitution**: Domestic brands are gaining market share due to supportive policies and technological advancements, with MicroPort EP and Huatai Medical leading in key areas [21]. 2. **Technological Innovation**: The industry is moving towards smart and precise technologies, enhancing the performance of electrophysiology devices and expanding clinical applications [22]. 3. **Growing Market Demand**: The demand for electrophysiology devices is surging, particularly in grassroots healthcare and international markets, with significant growth in overseas revenues for domestic companies [23].

Core Viewpoint - The high-end medical device industry in Shenzhen is a significant indicator of national manufacturing capability and technological development, with a projected revenue of 200 billion yuan by 2025, highlighting its importance in the global medical device market [1]. Group 1: Industry Overview - Shenzhen's medical device output reached 99 billion yuan in 2023, accounting for approximately 10% of the national total, with exports also around 10% [1]. - The city is home to leading companies like Mindray Medical and BGI, which are recognized among the top 100 global medical device firms [1]. Group 2: Technological Advancements - The brain-computer interface technology developed by Shenzhen Ruihan Medical has shown significant promise in rehabilitation, with patients experiencing better recovery outcomes compared to traditional methods [2][3]. - Ruihan Medical's brain-computer interface rehabilitation robot system is the first commercialized product of its kind globally, with over 100 patents and a focus on practical application [3]. Group 3: Collaborative Innovation - The National High-Performance Medical Device Innovation Center in Shenzhen is addressing core technological challenges in the medical device sector through collaborative projects with key enterprises [6][7]. - The center has successfully developed a 5.0T whole-body MRI system, marking a significant breakthrough in high-field MRI technology [6]. Group 4: Market Dynamics - The medical device industry in Shenzhen is characterized by a "chain development" model, where breakthroughs in technology stimulate growth across the entire supply chain [8]. - Companies like Mindray Medical and Libang Instruments have successfully disrupted international monopolies in their respective fields, leading to increased domestic production capabilities [9][10]. Group 5: Spatial and Policy Support - Shenzhen's medical device industry faces challenges such as limited industrial space, prompting local governments to create favorable conditions for business growth [11][12]. - The city has introduced comprehensive support measures for the medical and pharmaceutical sectors, aiming to solidify its position as a leading hub for medical device innovation [13].

Core Viewpoint - The company announced a temporary suspension of the conversion of its convertible bonds "乐普转2" during the repurchase period, which is set to last from May 19, 2025, to May 23, 2025, due to specific conditions being met for the bondholders to exercise their repurchase rights [1][2]. Group 1 - The company issued 16.38 billion yuan worth of convertible bonds on March 30, 2021, with a face value of 100 yuan per bond, totaling 16.38 million bonds [1]. - The conversion period for "乐普转2" is from October 8, 2021, until the stock price falls below 70% of the conversion price of 27.92 yuan per share for thirty consecutive trading days [1]. - The company held a bondholders' meeting on May 15, 2025, to approve changes to the use of raised funds, activating the additional repurchase clause for "乐普转2" [2]. Group 2 - The suspension of the conversion of "乐普转2" will last for five trading days, starting from May 19, 2025, and will resume on May 26, 2025 [2]. - During the suspension period, the convertible bonds will continue to trade normally [2].